Demetrice Grier, APRN
Psychiatric/Mental Health · Augusta, GANPI 1144678848
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,688 of the $7,231 with a category attached, or 64.8%. Neurocrine Biosciences, Inc. accounts for 65.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $5,606 and has fallen 98.1% since, to $107 in 2025. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $48.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$5K
- Alkermes, Inc.$752
- Johnson & Johnson$536
- AbbVie$432
- Otsuka America Pharmaceutical, Inc.$326
- Sunovion Pharmaceuticals Inc.$194
- plus $259 from 6 others
What the payments were for
- Consulting fees$4,68865%
- Food & beverage$2,54335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 5 | $4,732 |
| Alkermes, Inc. | 46 | $752 |
| Johnson & Johnson | 27 | $536 |
| AbbVie | 24 | $432 |
| Otsuka America Pharmaceutical, Inc. | 18 | $326 |
| Sunovion Pharmaceuticals Inc. | 13 | $194 |
| Lundbeck LLC | 4 | $75 |
| Indivior Inc. | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$4,688
How this compares
$7,231 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 22 | $39,885 |
| RexultiBrexpiprazole | 12 | $20,485 |
| Clozapine | 84 | $8,952 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $2,318 |
| Olanzapine | 54 | $1,635 |
| Haloperidol Decanoate | 50 | $1,475 |
| Quetiapine Fumarate | 79 | $1,165 |
| Aripiprazole | 29 | $1,160 |
| Benztropine Mesylate | 67 | $973 |
| Risperidone | 54 | $799 |
| Lurasidone Hcl | 13 | $713 |
| Haloperidol | 24 | $702 |
| Clonazepam | 14 | $284 |
| Divalproex Sodium | 21 | $192 |
| Buspirone Hcl | 21 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $536 | $39,88522 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $326 | $20,48512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Augusta
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
- Bradley MosherSuwanee$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.